Showing results (571-580 of 644) with videos related to
Sort By:
Pageof 65
Implementation Science Communications|August 10, 2023
Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorderCarla C Garcia, Mark Bounthavong, Adam J Gordon, et al.The American Journal of Hospice & Palliative Care|February 17, 2023
Implementation Costs of Technology-Enhanced Transitional Palliative Care for Rural CaregiversBrystana G Kaufman, Diane E Holland, Catherine E Vanderboom, et al.Archives of Pathology & Laboratory Medicine|December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialJohn M S Bartlett, Jason Christiansen, Mark Gustavson, et al.Circulation|February 27, 2020
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL OutcomesM Angelyn Bethel, Susanna R Stevens, John B Buse, et al.Journal of Pain and Symptom Management|August 7, 2024
Transitional Palliative Care for Family Caregivers: Outcomes From a Randomized Controlled TrialJoan M Griffin, Jay N Mandrekar, Catherine E Vanderboom, et al.Neurobiology of Aging|June 9, 2024
Brain reserve in midlife is associated with executive function changes across 12 yearsDaniel E Gustavson, Jeremy A Elman, Chandra A Reynolds, et al.Cardiovascular Diabetology|October 24, 2019
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trialLindsay E Clegg, Robert C Penland, Srinivas Bachina, et al.Scientific Reports|July 4, 2019
Maternal fever during pregnancy and offspring attention deficit hyperactivity disorderKristin Gustavson, Helga Ask, Eivind Ystrom, et al.Diabetes Care|December 7, 2019
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)Shelby D Reed, Yanhong Li, Helen A Dakin, et al.Clinical Pharmacology and Therapeutics|June 5, 2004
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levelsDavid A Katz, David R Grimm, Steven C Cassar, et al.Pageof 65